Literature DB >> 33137011

Management of Trichomoniasis in the Setting of 5-Nitroimidazole Hypersensitivity.

Olivia T Van Gerwen1, Andres F Camino2, Lorelei N Bourla3, Davey Legendre4, Christina A Muzny1.   

Abstract

ABSTRACT: Metronidazole and other 5-nitroimidazoles are the mainstay of Trichomonas vaginalis treatment, with few efficacious and safe treatment options available outside of this class. Patients with trichomoniasis and a history of a clinically confirmed hypersensitivity reaction to 5-nitroimidazoles present a management challenge for clinicians. The first step in managing such patients is metronidazole desensitization. In situations where this cannot be performed or tolerated, treatment with alternative regimens outside of the 5-nitroimidazole class, such as intravaginal boric acid or paromomycin, may be possible.
Copyright © 2020 American Sexually Transmitted Diseases Association. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33137011      PMCID: PMC8081757          DOI: 10.1097/OLQ.0000000000001326

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   3.868


  29 in total

1.  Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines.

Authors:  Kimberly A Workowski
Journal:  Clin Infect Dis       Date:  2015-12-15       Impact factor: 9.079

Review 2.  Drug allergy.

Authors:  David A Khan; Roland Solensky
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

3.  Metronidazole hypersensitivity and oral desensitization.

Authors:  M L Kurohara; F K Kwong; T B Lebherz; W B Klaustermeyer
Journal:  J Allergy Clin Immunol       Date:  1991-08       Impact factor: 10.793

4.  Results of the National Institute of Allergy and Infectious Diseases Collaborative Clinical Trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults.

Authors:  D D Sogn; R Evans; G M Shepherd; T B Casale; J Condemi; P A Greenberger; P F Kohler; A Saxon; R J Summers; P P VanArsdel
Journal:  Arch Intern Med       Date:  1992-05

5.  An association between Trichomonas vaginalis and high-risk human papillomavirus in rural Tanzanian women undergoing cervical cancer screening.

Authors:  Gweneth B Lazenby; Peyton T Taylor; Barbara S Badman; Emil McHaki; Jeffrey E Korte; David E Soper; Jennifer Young Pierce
Journal:  Clin Ther       Date:  2014-01-01       Impact factor: 3.393

6.  Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids.

Authors:  L V Allen; M A Erickson
Journal:  Am J Health Syst Pharm       Date:  1996-09-01       Impact factor: 2.637

Review 7.  Nitroimidazole drugs--action and resistance mechanisms. I. Mechanisms of action.

Authors:  D I Edwards
Journal:  J Antimicrob Chemother       Date:  1993-01       Impact factor: 5.790

8.  Prevalence and determinants of genital shedding of herpes simplex virus among women attending Italian colposcopy clinics.

Authors:  Fausto Boselli; Giuseppe Chiossi; Marisa Bortolamasi; Andrea Gallinelli
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2005-01-10       Impact factor: 2.435

9.  Hypersensitivity reactions to metronidazole.

Authors:  Isabel García-Rubio; Consuelo Martínez-Cócera; Sara Santos Magadán; Beatriz Rodríguez-Jiménez; Sonia Vázquez-Cortés
Journal:  Allergol Immunopathol (Madr)       Date:  2006 Mar-Apr       Impact factor: 1.667

Review 10.  Drug allergy.

Authors:  Richard Warrington; Fanny Silviu-Dan; Tiffany Wong
Journal:  Allergy Asthma Clin Immunol       Date:  2018-09-12       Impact factor: 3.406

View more
  1 in total

1.  Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.

Authors:  Patricia J Kissinger; Charlotte A Gaydos; Arlene C Seña; R Scott McClelland; David Soper; W Evan Secor; Davey Legendre; Kimberly A Workowski; Christina A Muzny
Journal:  Clin Infect Dis       Date:  2022-04-13       Impact factor: 20.999

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.